Binding Term Sheet Agreement ("Agreement") between Pharmaniaga Lifescience Sdn Bhd, a wholly-owned subsidiary of Pharmaniaga Berhad and Sinovac Life Sciences Co. Ltd.

We refer to Pharma’s announcement dated 12 January 2021 in respect of the aforesaid matter.
 

In this connection, kindly furnish Bursa Securities with the following additional information for public release:

1) Whether PLS possesses the required expertise, knowhow and resources to manufacture the Covid-19 vaccine.

2) The tentative timeframe to enter into the Local Manufacturing Agreement and a Technology and Know-How License       Agreement with SINOVAC LS.

3) The risks in relation to the manufacturing of the Covid-19 vaccine that PLS may be exposed to.

4) To elaborate the manner in which PLS intends to market and distribute the Covid-19 vaccine and whether any               contract has been secured todate.

5) To specify the relevant authorities’ approvals required for the clinical trial of the Covid-19 vaccine and the                       manufacturing, distribution and sale of the Covid-19 vaccine in Malaysia together with the status of approval,                 where applicable.

6) The estimated total capital outlay or costs to be incurred and the source of funding for the  manufacturing of Covid-      19 vaccine.

Please furnish Bursa Securities with your reply within one (1) market day from the date hereof.

Yours faithfully

Listing

Regulation

cc: Market Surveillance Dept.  Securities Commission (via fax)